Search

Author/Creator Zheng, Rongsheng

2. CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial. Issue 1 (24th May 2019)

Authors:
Shi, Yuankai; Li, Jin; Xu, Jianming; Sun, Yan; Wang, Liwei; Cheng, Ying; Liu, Wei; Sun, Guoping; Chen, Yigui; Bai, Li; Zhang, Yiping; He, Xiaohui; Luo, Yi; Wang, Zhehai; Liu, Yunpeng; Yao, Qiang; Li, Yuhong; Qin, Shukui; Hu, Xiaohua; Bi, Feng
Journal:
Cancer communications
Issue:
Volume 39:Issue 1(2019)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search